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Abstract 
A unique workshop was recently held focusing on enhancing collaborations leading to identify and update the 
development of therapeutic strategies targeting connexin/pannexin large pore channels. Basic scientists exploring 
the functions of these channels in various pathologies gathered together with leading pharma companies which are 
targeting gap junction proteins for specific therapeutic applications. This highlights how paths of discovery research 
can converge with therapeutic strategies in innovative ways to enhance target identification and validation.
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Background
The essential role of gap junction channels and hemichan-
nels in the normal functioning of cells and its relationship 
to diseases is only beginning to be understood. Gap junc-
tion channels assemble when connexins oligomerize into 
a connexon or hemichannel and dock with another from 
a neighboring cell [1]. These channels cluster at defined 
cell–cell contacts to form gap junctions, but they can also 
function as single membrane hemichannels, particularly 
in pathological situations [2] (Fig.  1). It is now appar-
ent that most human cells express more than one of the 
21 members of the connexin family. The complexity of 
channel constituents and arrangements within tissues is 
thought to be critical in selective passage of small biologi-
cal molecules, like second messengers, amino acids and 
metabolites. Alternatively, hemichannels allow direct 
communication between the cytosol and the extracellu-
lar space. Interestingly, mutations in the genes encoding 
several members of the connexin family have been linked 
to a number of human diseases [3]. In addition, the gen-
eration of connexin knockout (KO) mice has revealed 
a number of defects ranging from embryonic lethal to 
relatively normal animals [4]. The more recent discov-
ery of pannexins, which share sequence homology to the 
invertebrate gap junction proteins innexins, has broad-
ened the topic significantly [5] (Fig.  1). Pannexins form 
large single membrane channels serving a role in parac-
rine signaling that can be detrimental and contribute to 
cell death. These findings highlight the importance of 
connexins/pannexins in nearly every major organ in the 
body. Therapeutic interest arising from the biological 
insights of these proteins is beginning to gain momen-
tum and open the way to new therapeutic interventions. 
Therefore a unique and timely “Workshop on the interface 
between connexin/pannexin biology and therapeutics” 
was held in Paris March 3–4, 2016 for the research com-
munity to interface with Biotech and Pharma companies 
to accelerate the innovation and application of therapeu-
tics for a variety of diseases in which these channels are 
involved.
Regulation of expression and function
When considering a therapeutic biological target such as 
a membrane channel, basic aspects concerning expres-
sion, regulation and function are foundational. Following 
an overview presented by Dale Laird (Western University, 
Ontario, Canada), Paul Lampe (Fred Hutchinson Can-
cer Research Centre, Seattle, WA, USA) provided insight 
on the most widely expressed gap junction protein, con-
nexin43 (Cx43), particularly focusing on its phospho-
rylation at many amino acid residues in the cytoplasmic, 
C-terminal region [6]. These phosphorylation events, 
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channels, are mediated via a “kinase program” where 
sequential phosphorylations take place and affect Cx43 
channel functions. Interestingly, the complex regulation of 
channel assembly and turnover provides several opportu-
nities for potential drug intervention. Dale Laird explained 
how cell cultures and genetically-modified mouse models 
are used to investigate the genotype/phenotype relation-
ships in Cx43-linked diseases [3]. Using tissue-relevant cells 
derived from these mice along with patient cells, he deter-
mined the breadth of mechanisms linking Cx43 mutations 
to disease. For one such human disease, oculodentodigital 
dysplasia (ODDD), he has used the innovative approach 
of generating human induced pluripotent stem cells from 
patients and familial controls to examine the role of Cx43 
in the skeleton. He stressed that a multipronged approach 
is necessary to investigate the molecular basis of Cx43-
linked disease and that this approach allows identification 
of sub-classifications of disease-causing mutations neces-
sary for personalized therapeutic intervention.
At the heart of vascular diseases
Gap junctions sustain the regular heart beat. Thus it 
is no surprise to see innovations targeting gap junc-
tion channels with regard to cardiac disease. However, 
Fig. 1 Connexin and pannexin topology. Connexin and pannexin share a common structural topology despite the absence of sequence homol-
ogy. Both are transmembrane proteins with four transmembrane domains, two extracellular loops, one cytoplasmic loop, and cytoplasmic N– and 
C–terminal domains (a, c). Connexin and pannexin monomers both oligomerize to form a functional  ‘connexon’ and ‘pannexon’ channel, respec-
tively. However, only connexin channels can assemble into a gap junction that allows intercellular communication. Pannexin is glycosylated and 
large glycan residues prevent the docking of pannexin channels from adjacent cells (b, d). The amino acid sequences in a and c represent human 
Cx43 and Panx1 respectively. PTMs post-translational modifications. Figure contributed by Dr. M. Le Vasseur, University of British Columbia, Canada
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Mario Delmar (New York University, USA) has focused 
his work on channel-independent functions of Cx43. 
He has identified Cx43 in the heart as part of a molecu-
lar complex that includes molecules of the desmosome 
and of the sodium channel complex [7]. He proposed 
that Cx43 is part of a protein interacting network, “the 
connexome”, where all the proteins interacting with the 
gap junction protein contribute to cell adhesion, excit-
ability, and electrical coupling [8]. He found that loss of 
expression of plakophilin-2, an event responsible for an 
inherited cardiomyopathy, increases the release of ATP 
in a Cx43-dependent manner. Based on this, he proposed 
that the connexome could represent a target to interfere 
with paracrine-mediated initiation of a pro-fibrotic pro-
gram. Brenda Kwak (Université de Genève, Switzerland) 
spoke about atherosclerosis, an inflammatory disease 
of large- and medium-sized arteries and presented data 
indicating that hemichannels and gap junction channels 
play a role in atherogenesis [9]. Using mouse models for 
atherosclerosis, she has shown that Cx37 hemichannels 
control the initiation of atherosclerosis in mice by inhib-
iting autocrine ATP-dependent regulation of monocyte 
adhesion [10]. In addition, arterial blood flow patterns 
regulate Cx37 expression thereby inducing the forma-
tion of distinct communication compartments in the 
endothelium, with a segregation of athero-prone and 
-protected regions [11]. Moreover, connexins also play a 
channel-independent role in atherogenesis since a novel 
functional interaction between Cx40 and IκBα, a regu-
latory protein of NF-κB, has been found which could be 
relevant for the development of atherosclerotic disease.
Healing wounds
Skin is endowed with an extensive spatially distinct 
expression of various connexins. Patricia Martin (Glas-
gow Caledonian University, Scotland) reported changes 
in connexin expression and function associated with a 
range of epidermal disorders [12]. At the edge of chronic 
non-healing wounds Cx43 and Cx26 are up-regulated 
and blocking channel function or reducing Cx43 expres-
sion improves wound closure rates. In hyperproliferative 
skin disorders, such as psoriasis, Cx26 is dramatically up-
regulated, a hallmark for the disease state. She showed 
that pro-inflammatory challenge by opportunistic skin 
pathogens prevalent in non-healing wounds and psori-
atic plaques induces Cx26 expression in keratinocytes, 
activates hemichannels and induces expression of pro-
inflammatory cytokines [13]. Blocking Cx hemichannel 
reduces pro-inflammatory mediated events suggesting 
that specific connexin channel blockers may provide a 
strategy to reduce skin inflammation.
Brain diseases
With up to 12 different connexins and 2 pannexins 
detected in the brain, these channel proteins may also 
represent therapeutic targets for neurological disorders 
[14]. Annette Koulakoff (Collège de France, Paris) showed 
that the expression of Cxs in astroglia is increased at 
the level of amyloid plaques, a typical histopathological 
lesion in brains of patients and murine models of Alz-
heimer’s disease (APP/PS1 mouse). She reported that in 
this mouse, gap junctional communication (GJC) is not 
affected in astrocytes, while hemichannels are chronically 
activated. Cx43 is the main hemichannel contributor 
activated by the increase in intracellular calcium levels. 
Importantly, hemichannel activation leads to a release of 
ATP and glutamate that contributes to maintain a high 
calcium level placing astrocytes at the center of a vicious 
cycle. Astroglial targeted Cx43 gene KO in APP/PS1 mice 
diminishes gliotransmitter release and alleviates neuronal 
damage, suggesting that blocking hemichannel activity in 
astrocytes may represent an alternative therapeutic strat-
egy to reduce neuronal suffering in Alzheimer’s disease 
[15]. Peter Bedner (Bonn University, Germany) analyzed 
functional properties of astrocytes in hippocampal speci-
mens from patients with mesial temporal lobe epilepsy 
(MTLE) with and without hippocampal sclerosis (MTLE-
HS). He found that the sclerotic human hippocampus 
is completely devoid of bona fide astrocytes and GJC. 
Employing a new mouse model of MTLE-HS, he showed 
that reduction in GJC and the consequential impairment 
of extracellular potassium clearance precedes neuronal 
death and the onset of spontaneous seizure activity. A 
similar feature was observed in another seizure model, 
hyperthermia-induced febrile convulsions, providing 
strong evidence that dysfunction of astroglial GJC rep-
resents a fundamental mechanism in epileptogenesis 
[16]. In related studies, Juan Saez (Catholic University 
of Chile, Santiago) examined neuroinflammation trig-
gered in adult mice treated acutely or chronically with 
epileptogenic compounds or in the brain of the offspring 
from mothers treated with high glucocorticoid levels 
during pregnancy. Under these conditions the activ-
ity of pannexin1 and connexin hemichannels is drasti-
cally increased in mast cells, microglia and macroglia, 
including astrocytes. Treatment with a selective connexin 
hemichannel blocker normalizes the EEG in epilepsy and 
eliminates convulsions in these mice. The Bedner and 
Saez results address different functions of these channel 
proteins, as connexin mediated channels contributing 
to a functional neuroglial interaction either through gap 
junction-mediated networking or hemichannel-mediated 
release/uptake pathways, respectively. Finally, Christian 
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Naus (University of British Columbia, Canada) reported 
that connexin and pannexin channels provide intercel-
lular pathways through which neuronal, glial, and vascu-
lar tissues interact. In the brain, this interaction is highly 
critical for homeostasis and brain repair after injury. He 
presented current insights and emerging concepts, par-
ticularly the impact of Cx43 and pannexin1, under neu-
roprotective and neurodegenerative conditions in stroke 
within the context of astrocytes [17]. Specifically block-
ing Cx43 hemichannels using the Gap19 mimetic peptide 
[18] (Fig.  2) provided significant neuroprotection in a 
mouse ischemic stroke model. Furthermore, he reported 
that pannexin1 KO mice showed a sex-specific neuropro-
tective effect in stroke; this could also be shown using the 
pannexin1 channel blocker, probenecid.
Cancer
Cancer, and in particular glioma, was also considered. 
Marc Mesnil (Université de Poitiers, France) noted that 
the most common brain tumor in adults, glioblastoma 
(grade IV glioma) is not curable because of recurrence 
due to high invasion capacity. In a study covering glio-
mas from grades II to IV (85 tumors), he observed that 
even if Cx43 expression decreases in higher grade tumors 
some glioblastoma cells still express it. He mentioned 
experimental data suggesting that lack of Cx43 expres-
sion favors cell proliferation while its presence increases 
invasion capacity. This was confirmed using human 
glioblastoma cells in which Cx43 was detected in inva-
dopodia able to digest gelatin. Decreasing its expression 
by shRNAs demonstrated that Cx43 favors invadopodia 
growth while its hemichannel function inhibits this pro-
cess. Preliminary data suggest that Cx43 permits inter-
actions between c-Src and cortactin, necessary for actin 
polymerization and thus for invadopodia elongation 
independently from mediation of GJC. Confirmation of 
these molecular mechanisms might lead to therapeu-
tics targeting Cx43 to prevent invasion and recurrence 
of glioblastomas [19]. Consistent with these findings, 
Arantxa Tabernero (University of Salamanca, Spain) 
noted that c-Src interacts with Cx43 through its SH3 
binding domain and phosphorylates Tyr265, providing 
an SH2 binding domain site with subsequent phospho-
rylation at Tyr247. As a consequence, GJC is reduced, 
and Cx43 turnover is initiated. She revealed that the 
interaction between Cx43 and c-Src inhibits c-Src activity 
[20]. Also, gain- and loss-of-function experiments, car-
ried out in glioma cells and astrocytes, showed that Cx43 
and c-Src are mutually regulated by a phosphorylation/
dephosphorylation loop. Accordingly, results obtained 
with cell-penetrating peptides containing the Src-inter-
acting region show that a short peptidic sequence is suf-
ficient to mimic the effect of Cx43 on the inhibition of 
c-Src activity. Thus, the region of 266–283 amino acids of 
Cx43 (PEP-2 in Fig. 2) could help to develop new drugs 
that target diseases, such as glioma or neuroinflamma-
tion, in which the over-activation of c-Src needs to be 
reduced [21, 22]. Finally, Robert Gourdie (Center for 
Heart and Regenerative Medicine, Roanoke) indicated 
that the standard-of-care treatment for glioblastoma 
involves surgery to remove the tumor, followed by radia-
tion and chemotherapy. Unfortunately, this treatment is 
largely ineffective as tumors recur and a main reason for 
this failure is that patients develop resistance to chemo-
therapy [23, 24]. He mentioned that Cx43 is a key deter-
minant of chemotherapy resistance and that the Cx43 
inhibitory peptide αCT1 (CT9 in Fig.  2) recovers the 
sensitivity of human glioblastoma cells and glioma stem 
cells to chemotherapy in vitro and in glioblastoma animal 
models in vivo [25]. To reformulate αCT1 for internal use 
in brain tumors, αCT1 can be encapsulated in an FDA-
approved polymer to provide for its controlled-release 
in  situ following delivery into brain tumors. The release 
kinetics of αCT1 from the polymer vehicle has been con-
firmed in vitro over 3 weeks with uptake and dissolution. 
The controlled-release αCT1 formulation is presently 
being tested in combination with chemotherapy in a clin-
ical trial in dogs with naturally occurring high-grade gli-
oma. The first of the canine patients entered the protocol 
in April 2016 and it is expected that 6–8 dogs will have 
received the combined treatment by the end of 2016. If 
safety outcomes are favorable, he anticipates seeking reg-
ulatory approval from the FDA to advance to clinical tri-
als in humans in 2017.
Chronic diseases: kidney and lung
Next, the presentation of Christos Chadjichristos 
(INSERM, Paris) was focused on Cx43 being a new ther-
apeutic target against chronic kidney disease (CKD). 
Excessive recruitment of monocytes and progression of 
fibrosis are hallmarks of CKD. Cx43 expression is highly 
increased within damaged compartments of the kidney 
during the progression of CKD in humans and rodents. 
Reduced expression of Cx43 in a hypertension-induced 
nephropathy model in mice shows a marked decrease 
of cell adhesion markers leading to reduced monocyte 
infiltration and interstitial renal fibrosis. Accordingly, 
functional and histological parameters such as albumi-
nuria and glomerulosclerosis are substantially amelio-
rated. Furthermore, short-term treatment with Cx43 
antisense produced remarkable improvement of renal 
function and structure in mice at a very advanced stage 
of hypertension-induced kidney disease [26]. The bene-
ficial effect of Cx43 antisense was observed in additional 
models of experimental nephropathy confirming that 
the beneficial effect of Cx43 blockade can be considered 
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as a general protective strategy against renal disease. He 
concluded that Cx43 might represent a new therapeutic 
target against the progression of CKD. Marc Chanson 
(Université de Genève, Switzerland) talked about air-
way epithelial infection with a focus on connexin and 
host-pathogen interaction in cystic fibrosis (CF) airway 
disease. Respiratory tract infections are hallmarks of 
CF, a hereditary disease caused by mutations of the CF 
transmembrane conductance regulator (CFTR) gene. 
An understanding of the interaction between host and 
pathogen is essential for effective prevention and con-
trol of infectious diseases. In this context, he reported 
that Cx43 in polarized airway epithelial cells is a target 
of P. aeruginosa via toll-like receptor 5 (TLR5) activa-
tion, leading to its increased functional expression 
by means of interplay between p38 and JNK MAPKs 
[27]. He further showed that GJC modulates airway 
cell apoptosis, a defense mechanism that is altered 
after CFTR silencing. He found that CFTR intersects 
with JNK-signaling to modulate Cx43 expression and 
Fig. 2 Schmematic of Cx43 amino acid sequence showing portions of the protein which have been targeted with mimetic peptides. See text for 
details. The commonly used mimetic peptides, Gap26 and Gap 27, are shown for reference. Figure contributed by Dr. L. Leybaert, Ghent University, 
Belgium
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apoptosis, suggesting that CFTR dysfunction may alter 
the apoptosis/inflammation balance in CF.
Therapeutic strategies
Therapeutic approaches designed to target connexins and 
pannexins involved in disease were an integral part of this 
workshop. These consisted of approaches to target specific 
functional aspects of these channels. Luc Leybaert (Gent 
University, Belgium) presented connexin hemichannel 
targeting peptides as tools to protect against cell injury 
and cell death. He stated that while GJC has major physi-
ological roles, connexin hemichannels are thought to have 
mostly detrimental effects. As a result, there is a strong 
need for specific hemichannel blockers that do not affect 
GJC. He demonstrated that peptides like L2 and Gap19 
(Fig. 2) specifically block Cx43-based hemichannels with-
out affecting GJC. Their effect is based on blocking the 
interaction between the cytoplasmic loop and the C-termi-
nal tail of Cx43. Recent work with the hemichannel block-
ing peptide RRNYRRNY, the design of which is based on 
the pharmacophore for CL to CT binding, has the advan-
tage to counteract gap junction channel closure [18, 28]. 
He also found that this peptide blocks mitochondrial Cx43 
hemichannels and mitochondrial calcium ion uptake, 
thereby protecting against cell death. Finally, he proposed 
that connexin channels could be targeted at three levels: 
the gap junction channels, the hemichannels in the plasma 
membrane and the mitochondrial hemichannels.
As an critical innovative aspect of this meeting, Pharma 
and Biotech companies, having a common interest in 
connexins as potential therapeutical targets, revealed 
their targeting strategies. Gautam Ghatnekar (FirstString 
Research, USA) gave an overview of their focus on scar 
prevention, inflammation reduction, wound healing, and 
complex tissue regeneration. He claimed that Cx43 is a 
novel therapeutic target with the potential to manipulate 
the body’s injury response. With this objective FirstString 
has implemented a 25aa peptide (αCT1) with a compact 
2-domain design based on linkage of an antennapedia 
internalization domain to the C-terminal PDZ binding 
domain of Cx43 (CT9 in Fig.  2), originally reported by 
Gourdie and colleagues [29]. When applied on cutaneous 
wounds, αCT1 restores GJC that is lost in injured tissues 
and reduces excessive inflammatory responses character-
izing chronic wounds [30]. This reestablishes a normal 
wound repair cascade, accelerates re-epithelialization, 
and prevents excessive fibrosis. αCT1’s design enables 
translocation within cells and inhibition of the interaction 
between Cx43 and zonula occludens-1 (ZO-1). Such inhi-
bition leads to phosphorylation of Ser368 on Cx43, and 
cellular redistribution of Cx43. The result is a transition 
of cell-surface Cx43 from hemichannels to gap junction 
channels, enhancing the stability of gap junction channel 
aggregates, reducing hemichannel activity and temper-
ing inflammatory responses. FirstString Research is cur-
rently advancing a topical αCT1 formulation (Granexin®) 
through pivotal human clinical trials for acute and chronic 
cutaneous wounds. Three phase 2 (n = 276) clinical trials 
validate the clinical potential of Granexin® in accelerat-
ing the closure of refractory diabetic foot ulcers [31] and 
venous leg ulcers [32], and in the mitigation of acute sur-
gical incision scars. Results of clinical trials support the 
tolerability and clinically significant efficacy of αCT1 in 
the treatment of acute and chronic wounds. Its beneficial 
effects in cutaneous wound healing translate easily to the 
treatment of other injury pathologies similarly defined 
within the context of connexin signaling. Mathieu Char-
vériat (Theranexus, France) presented data on astroglial 
connexins and modafinil efficacy. Modafinil is a stand-
ard of care used in narcolepsy, a rare disease character-
ized by excessive daytime sleepiness, and it modulates 
astroglial GJC [33]. He presented findings in mice on the 
impact of GJC on the effects of modafinil using flecainide, 
an anti-arrhythmic registered drug repurposed as an 
astroglial GJC inhibitor [34]. Indeed, modafinil enhances 
astrocyte GJC and he demonstrated that this modafinil-
induced effect on GJC was prevented by co-administra-
tion with flecainide. He also established that flecainide 
enhanced the wake-promoting and pro-cognitive effects 
of modafinil; in addition modafinil/flecainide treatment 
resulted in a decrease in the number of narcoleptic epi-
sodes. This study indicates that flecainide improves the 
pharmacological profile of modafinil, likely through the 
normalization of GJC in astroglial networks, opening 
new perspectives in the management of narcolepsy. In 
fact, Theranexus recently been announced the results of a 
proof of concept clinical trial in excessive daytime sleepi-
ness (EDS) induced by sleep deprivation in healthy volun-
teers. THN102 (combination of modafinil and flecainide, 
repurposed at low dose as a glial connexin modulator) has 
a beneficial effect on vigilance and cognition throughout 
the sleep deprivation when compared to the standard of 
care modafinil. Finally, Rie Hansen and Anneline Nansen 
(Zealand Pharma A/S, Smedeland, Denmark) spoke 
about this biotech company’s leading scientific expertise 
in turning peptides into medicines with several libraries 
of gap junction modulating compounds. These include a 
library of 200 Cx43 CT interacting compounds from 40 
mer peptides to modified tripeptides, a library of 20 Cx37 
CT-interacting peptides, a library related to danegaptide/
rotigaptide (zealandpharma.com) that contains 500 com-
pounds, including hexapeptides, cyclic peptides, modi-
fied dipeptides and small molecules, a library containing 
of 150 modified Gap-peptides, GJC/pannexin1 inhibi-
tors against Cx43, 40, 36, 32, 31.1, 26 and pannexin1, and 
many more. Zealand is willing to share the compounds for 
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scientific investigation under a material transfer agree-
ment. Within the gap junction field Zealand is running a 
project focused on accelerated dermal wound healing by 
specific Cx43 inhibition. Furthermore, Zealand has very 
recently conducted a phase 2 study focused to treat rep-
erfusion injury after acute myocardial infarction, with 
danegaptide, a modulator of Cx43. Unfortunately, this 
study did not meet its primary endpoint. Another com-
pany, CoDa Therapeutics Inc., was, unfortunately, unable 
to participate in the meeting. CoDa has three connexin 
channel modulators in clinical development, in the first 
instance for chronic skin wounds and ocular disease. 
These are an antisense oligodeoxynucleotide (Nexagon®) 
which transiently downregulates Cx43 protein expression, 
an extracellular acting Cx43 peptidomimetic that can be 
delivered locally or systemically (Peptagon™) (Peptide 5 
in Fig. 2) and a small molecule for systemic or oral deliv-
ery (HCB1019) [35]. The latter two are specifically used to 
target hemichannels. Nexagon® and HCB1019 are Phase 
III ready. CoDa has focused significant activity on the 
connexin hemichannel and has demonstrated efficacy in 
a number of skin, eye and central nervous system injury 
and disease animal models where hemichannel block, 
or transient down regulation of Cx43, reduces oedema, 
inflammation, vascular leak and lesion spread [36]. In 
human eye burns for example, reduced inflammation and 
recovery of vascular integrity following down regulation 
of Cx43, leads to epithelial recovery and healing [37].
Summary and future directions
Considerable insights continue to emerge regarding the 
biology of connexins and pannexins, and their possible 
roles in health and disease. With the knowledge of tissue 
distribution combined with deeper analysis of structure 
and the functions of these channel proteins, novel thera-
peutic approaches are impacting various diseases. Presen-
tations and discussions held during this workshop revealed 
new lines of research and identified overlapping fields of 
interest between fundamental life science and biotech ini-
tiatives. These can be grouped into several categories. (1) 
With regard to channel functions, drugs specifically target-
ing connexin channel versus hemichannel configurations 
will prove beneficial. These have focused on small peptide 
candidates. In this regard, Gap19 blocks Cx43 hemichan-
nels while αCT1 enhances Cx43 gap junction plaque for-
mation. Peptides containing the Src-interacting region 
can modulate kinase interactions with Cx43. Considerable 
efforts continue to be focused on exploring novel peptide 
therapeutics. (2) Non-channel functions of Cx43 are also 
being identified and their targeting should also open the 
way to new intervention strategies. (3) Specific effects can 
also be expected by targeting the “connexome” of interact-
ing proteins and their associated signaling pathways. (4) 
Finally, combinatorial approaches using connexin targeting 
combined with other drugs are emerging as a promising 
strategy. Based on the outcome of this workshop, there is 
considerable optimism with regard to bridging the gap to 
therapeutic strategies based on connexin/pannexin biology.
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